Treatment Tied to Survival Benefit in Complex Bladder Cancer

The researchers found that treatment was associated with a 30% reduction in death, while having multiple complex conditions was associated with a 72% increase in death in unweighted multivariable analysis.

HealthDay News — Cancer treatment is associated with a clinically meaningful survival benefit in older, medically complex patients with superficial bladder cancer (SBC), according to a study published online October 5 in Cancer.

Tullika Garg, MD, MPH, from Geisinger in Danville, Pennsylvania, and colleagues evaluated the association between treatment of SBC and 10-year mortality in 1800 medically complex patients aged ≥60 years. 

Related Articles

Overall, 1485 patients (82.5%) received treatment and 315 patients (17.5%) underwent observation. The researchers found that treatment was associated with a 30% reduction in death, while having multiple complex conditions (MCC) was associated with a 72% increase in death in unweighted multivariable analysis. There was also a survival benefit for treatment in weighted analysis with adjustment (adjusted hazard ratio, 0.66).

“These data provide a foundation for future work aimed at personalizing the treatment guidance of older patients with cancer with MCC,” the authors write.

Abstract/Full Text (subscription or payment may be required)